(Q40439562)

20 September 2017

title

Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy (English)

1 reference

20 September 2017

0 references

0 references

0 references

Bokarewa M

1

1 reference

20 September 2017

Lindholm C

2

1 reference

20 September 2017

Zendjanchi K

3

1 reference

20 September 2017

Nadali M

4

1 reference

20 September 2017

Tarkowski A

5

1 reference

20 September 2017

language of work or name

1 reference

1 October 2007

1 reference

Scandinavian Journal of Immunology

20 September 2017

published in

1 reference

20 September 2017

volume

66

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

476-483

1 reference

Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

B cells move to centre stage: novel opportunities for autoimmune disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3083.2007.01995.X

10.1111/J.1365-3083.2007.01995.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference